Okay here is what I have, feel free to copy, change, fix and repost. Tomorrow morning I will see where we are. Maybe I can take that old graphic and make a new similar one but with Short Term Catalysts (assuming I can get it all on one page)
Estimates on Potential Short Term Catalysts
March-April
non-dilutive financing licensing/partnerships
-multiple offers recieved from commercialization companies with significant upfront and milestone payments
-large biologics manufacturing $500M product for 2020 with delayed payment
Rolling BLA Review HIV Combo Part 1 submission
Monothearpy Pivotal Phase 3 Trial IND submission
TNBC Phase 2 Trial first patient injected
April-May
TNBC preliminary CTC numbers 21 days after patients injected
TNBC trial ODD and FTD approval
GvHD Phase 2 trial first patient injected
Melanoma, Pancreatic, Breast, Prostate, Colon, Lung, Liver, and Stomach Cancer Animal Trials Preliminary Data
Colon Cancer IND submission Phase 2 Trial
June-July
100 patient safety data on 700mg complete for BLA
-no serious adverse effects in over 700 patients to date unlike most or all other HIV drugs
July-September
BLA Complete Submission
--81% efficacy at 24 weeks vs already approved drugs 43% at 24 weeks and 45% at 48 weeks
2019
Prostate Cancer Test 510(k) filing
GvHD Interum Results
Colon Cancer ODD approval
TBA
Licensing/Partnership
-Prognostic Prostate Cancer PCa Test: interested potential partner
NASH, RA, MS Animal Studies/Phase 2 Trials
Estimates on Potential Short Term Catalysts
March-April
non-dilutive financing licensing/partnerships
-multiple offers recieved from commercialization companies with significant upfront and milestone payments
-large biologics manufacturing $500M product for 2020 with delayed payment
Rolling BLA Review HIV Combo Part 1 submission
Monothearpy Pivotal Phase 3 Trial IND submission
TNBC Phase 2 Trial first patient injected
April-May
TNBC preliminary CTC numbers 21 days after patients injected
TNBC trial ODD and FTD approval
GvHD Phase 2 trial first patient injected
Melanoma, Pancreatic, Breast, Prostate, Colon, Lung, Liver, and Stomach Cancer Animal Trials Preliminary Data
Colon Cancer IND submission Phase 2 Trial
June-July
100 patient safety data on 700mg complete for BLA
-no serious adverse effects in over 700 patients to date unlike most or all other HIV drugs
July-September
BLA Complete Submission
--81% efficacy at 24 weeks vs already approved drugs 43% at 24 weeks and 45% at 48 weeks
2019
Prostate Cancer Test 510(k) filing
GvHD Interum Results
Colon Cancer ODD approval
TBA
Licensing/Partnership
-Prognostic Prostate Cancer PCa Test: interested potential partner
NASH, RA, MS Animal Studies/Phase 2 Trials
1
